Cargando…
Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment
INTRODUCTION: Unwanted drug interactions with ionic currents in the heart can lead to an increased proarrhythmic risk to patients in the clinic. It is therefore a priority for safety pharmacology teams to detect block of cardiac ion channels, and new technologies have enabled the development of auto...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135079/ https://www.ncbi.nlm.nih.gov/pubmed/23651875 http://dx.doi.org/10.1016/j.vascn.2013.04.007 |
_version_ | 1782330934914187264 |
---|---|
author | Elkins, Ryan C. Davies, Mark R. Brough, Stephen J. Gavaghan, David J. Cui, Yi Abi-Gerges, Najah Mirams, Gary R. |
author_facet | Elkins, Ryan C. Davies, Mark R. Brough, Stephen J. Gavaghan, David J. Cui, Yi Abi-Gerges, Najah Mirams, Gary R. |
author_sort | Elkins, Ryan C. |
collection | PubMed |
description | INTRODUCTION: Unwanted drug interactions with ionic currents in the heart can lead to an increased proarrhythmic risk to patients in the clinic. It is therefore a priority for safety pharmacology teams to detect block of cardiac ion channels, and new technologies have enabled the development of automated and high-throughput screening assays using cell lines. As a result of screening multiple ion-channels there is a need to integrate information, particularly for compounds affecting more than one current, and mathematical electrophysiology in-silico action potential models are beginning to be used for this. METHODS: We quantified the variability associated with concentration-effect curves fitted to recordings from high-throughput Molecular Devices IonWorks® Quattro™ screens when detecting block of I(Kr) (hERG), I(Na) (NaV1.5), I(CaL) (CaV1.2), I(Ks) (KCNQ1/minK) and I(to) (Kv4.3/KChIP2.2), and the Molecular Devices FLIPR® Tetra fluorescence screen for I(CaL) (CaV1.2), for control compounds used at AstraZeneca and GlaxoSmithKline. We examined how screening variability propagates through in-silico action potential models for whole cell electrical behaviour, and how confidence intervals on model predictions can be estimated with repeated simulations. RESULTS: There are significant levels of variability associated with high-throughput ion channel electrophysiology screens. This variability is of a similar magnitude for different cardiac ion currents and different compounds. Uncertainty in the Hill coefficients of reported concentration-effect curves is particularly high. Depending on a compound’s ion channel blocking profile, the uncertainty introduced into whole-cell predictions can become significant. DISCUSSION: Our technique allows confidence intervals to be placed on computational model predictions that are based on high-throughput ion channel screens. This allows us to suggest when repeated screens should be performed to reduce uncertainty in a compound’s action to acceptable levels, to allow a meaningful interpretation of the data. |
format | Online Article Text |
id | pubmed-4135079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
record_format | MEDLINE/PubMed |
spelling | pubmed-41350792014-08-18 Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment Elkins, Ryan C. Davies, Mark R. Brough, Stephen J. Gavaghan, David J. Cui, Yi Abi-Gerges, Najah Mirams, Gary R. J Pharmacol Toxicol Methods Article INTRODUCTION: Unwanted drug interactions with ionic currents in the heart can lead to an increased proarrhythmic risk to patients in the clinic. It is therefore a priority for safety pharmacology teams to detect block of cardiac ion channels, and new technologies have enabled the development of automated and high-throughput screening assays using cell lines. As a result of screening multiple ion-channels there is a need to integrate information, particularly for compounds affecting more than one current, and mathematical electrophysiology in-silico action potential models are beginning to be used for this. METHODS: We quantified the variability associated with concentration-effect curves fitted to recordings from high-throughput Molecular Devices IonWorks® Quattro™ screens when detecting block of I(Kr) (hERG), I(Na) (NaV1.5), I(CaL) (CaV1.2), I(Ks) (KCNQ1/minK) and I(to) (Kv4.3/KChIP2.2), and the Molecular Devices FLIPR® Tetra fluorescence screen for I(CaL) (CaV1.2), for control compounds used at AstraZeneca and GlaxoSmithKline. We examined how screening variability propagates through in-silico action potential models for whole cell electrical behaviour, and how confidence intervals on model predictions can be estimated with repeated simulations. RESULTS: There are significant levels of variability associated with high-throughput ion channel electrophysiology screens. This variability is of a similar magnitude for different cardiac ion currents and different compounds. Uncertainty in the Hill coefficients of reported concentration-effect curves is particularly high. Depending on a compound’s ion channel blocking profile, the uncertainty introduced into whole-cell predictions can become significant. DISCUSSION: Our technique allows confidence intervals to be placed on computational model predictions that are based on high-throughput ion channel screens. This allows us to suggest when repeated screens should be performed to reduce uncertainty in a compound’s action to acceptable levels, to allow a meaningful interpretation of the data. 2013-05-05 2013 /pmc/articles/PMC4135079/ /pubmed/23651875 http://dx.doi.org/10.1016/j.vascn.2013.04.007 Text en © 2013 The Authors. Published by Elsevier Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Article Elkins, Ryan C. Davies, Mark R. Brough, Stephen J. Gavaghan, David J. Cui, Yi Abi-Gerges, Najah Mirams, Gary R. Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment |
title | Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment |
title_full | Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment |
title_fullStr | Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment |
title_full_unstemmed | Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment |
title_short | Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment |
title_sort | variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135079/ https://www.ncbi.nlm.nih.gov/pubmed/23651875 http://dx.doi.org/10.1016/j.vascn.2013.04.007 |
work_keys_str_mv | AT elkinsryanc variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment AT daviesmarkr variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment AT broughstephenj variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment AT gavaghandavidj variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment AT cuiyi variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment AT abigergesnajah variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment AT miramsgaryr variabilityinhighthroughputionchannelscreeningdataandconsequencesforcardiacsafetyassessment |